Infliximab for the Prevention of Graft-versus-Host Disease Following Allogenic Hematopoietic Stem Cell Transplantation
Status:
Completed
Trial end date:
2008-03-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the efficacy of infliximab in reducing the incidence of grade II-IV
acute graft versus host disease by day +100 post-transplant in patients undergoing allogeneic
hematopoietic stem cell transplant.